Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies

BACKGROUND: Rituximab (RTX), a monoclonal antibody that selectively binds to CD20+ B cells, showed favorable outcomes in patients with idiopathic inflammatory myopathies (IIM) in small case series, but the evidence is still not enough. Our goal was to determine the efficacy and safety of RTX for Kor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Korean Med Sci
Hlavní autoři: Ahn, Ga Young, Suh, Chang-Hee, Kim, Yong-Gil, Park, Yong-Beom, Shim, Seung Cheol, Lee, Sang-Heon, Lee, Shin-Seok, Bae, Sang-Cheol, Yoo, Dae Hyun
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Academy of Medical Sciences 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7521958/
https://ncbi.nlm.nih.gov/pubmed/32989931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2020.35.e335
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky